We demonstrate that tracking reduction of ASGPR levels can be useful for monitoring NASH progression, analogous to the way in which ASGPR reduction can be followed by computed tomography to monitor progression of hepatocellular carcinoma and cirrhosis.[45]We have demonstrated the ability to follow, noninvasively and longitudinally, NASH progression based on gradual downregulation of ASGPR using PET detection of GN probes that specifically target hepatocytes. Here, ASGR1 is linked to metabolic dysfunction-associated steatohepatitis.